These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 34196431)

  • 1. SARS-CoV-2 virulence evolution: Avirulence theory, immunity and trade-offs.
    Alizon S; Sofonea MT
    J Evol Biol; 2021 Dec; 34(12):1867-1877. PubMed ID: 34196431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do pathogens always evolve to be less virulent? The virulence-transmission trade-off in light of the COVID-19 pandemic.
    Kun Á; Hubai AG; Král A; Mokos J; Mikulecz BÁ; Radványi Á
    Biol Futur; 2023 Jun; 74(1-2):69-80. PubMed ID: 37002448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional mutations of SARS-CoV-2: implications to viral transmission, pathogenicity and immune escape.
    Dang S; Ren L; Wang J
    Chin Med J (Engl); 2022 May; 135(10):1213-1222. PubMed ID: 35788093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virulence evolution and the trade-off hypothesis: history, current state of affairs and the future.
    Alizon S; Hurford A; Mideo N; Van Baalen M
    J Evol Biol; 2009 Feb; 22(2):245-59. PubMed ID: 19196383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Escape Associated with RBD Omicron Mutations and SARS-CoV-2 Evolution Dynamics.
    Kudriavtsev AV; Vakhrusheva AV; Novosеletsky VN; Bozdaganyan ME; Shaitan KV; Kirpichnikov MP; Sokolova OS
    Viruses; 2022 Jul; 14(8):. PubMed ID: 35893668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune response and potential therapeutic strategies for the SARS-CoV-2 associated with the COVID-19 pandemic.
    Li X; Zhang Y; He L; Si J; Qiu S; He Y; Wei J; Wang Z; Xie L; Li Y; Teng T
    Int J Biol Sci; 2022; 18(5):1865-1877. PubMed ID: 35342348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emergence of Covid-19: evolution from endemic to pandemic.
    Ahsan H; Arif A; Ansari S; Khan FH
    J Immunoassay Immunochem; 2022 Jan; 43(1):22-32. PubMed ID: 34672900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism.
    Policard M; Jain S; Rego S; Dakshanamurthy S
    Virus Res; 2021 Aug; 301():198464. PubMed ID: 34058265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System.
    Banoun H
    Nephron; 2021; 145(4):392-403. PubMed ID: 33910211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interaction between SARS-CoV-2 and Host Innate Immunity].
    Duan XQ; Xie H; Chen LM
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2022 Jan; 53(1):1-6. PubMed ID: 35048592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why COVID-19 Transmission Is More Efficient and Aggressive Than Viral Transmission in Previous Coronavirus Epidemics?
    Elrashdy F; Redwan EM; Uversky VN
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32933047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental manipulation of immune-mediated disease and its fitness costs for rodent malaria parasites.
    Long GH; Chan BH; Allen JE; Read AF; Graham AL
    BMC Evol Biol; 2008 Apr; 8():128. PubMed ID: 18447949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 Variant Delta Potently Suppresses Innate Immune Response and Evades Interferon-Activated Antiviral Responses in Human Colon Epithelial Cells.
    Tandel D; Sah V; Singh NK; Potharaju PS; Gupta D; Shrivastava S; Sowpati DT; Harshan KH
    Microbiol Spectr; 2022 Oct; 10(5):e0160422. PubMed ID: 36073824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of host resistance and trade-offs between virulence and transmission potential in an obligately killing parasite.
    Bérénos C; Schmid-Hempel P; Wegner KM
    J Evol Biol; 2009 Oct; 22(10):2049-56. PubMed ID: 19732263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 will continue to circulate in the human population: an opinion from the point of view of the virus-host relationship.
    Oberemok VV; Laikova KV; Yurchenko KA; Fomochkina II; Kubyshkin AV
    Inflamm Res; 2020 Jul; 69(7):635-640. PubMed ID: 32350571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unraveling the Dynamics of Omicron (BA.1, BA.2, and BA.5) Waves and Emergence of the Deltacton Variant: Genomic Epidemiology of the SARS-CoV-2 Epidemic in Cyprus (Oct 2021-Oct 2022).
    Chrysostomou AC; Vrancken B; Haralambous C; Alexandrou M; Gregoriou I; Ioannides M; Ioannou C; Kalakouta O; Karagiannis C; Marcou M; Masia C; Mendris M; Papastergiou P; Patsalis PC; Pieridou D; Shammas C; Stylianou DC; Zinieri B; Lemey P; The Comessar Network ; Kostrikis LG
    Viruses; 2023 Sep; 15(9):. PubMed ID: 37766339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of human respiratory virus epidemics.
    Rochman N; Wolf Y; V Koonin E
    F1000Res; 2021; 10():447. PubMed ID: 34484689
    [No Abstract]   [Full Text] [Related]  

  • 19. N7-Methylation of the Coronavirus RNA Cap Is Required for Maximal Virulence by Preventing Innate Immune Recognition.
    Pan R; Kindler E; Cao L; Zhou Y; Zhang Z; Liu Q; Ebert N; Züst R; Sun Y; Gorbalenya AE; Perlman S; Thiel V; Chen Y; Guo D
    mBio; 2022 Feb; 13(1):e0366221. PubMed ID: 35073761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. There is no "origin" to SARS-CoV-2.
    Frutos R; Pliez O; Gavotte L; Devaux CA
    Environ Res; 2022 May; 207():112173. PubMed ID: 34626592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.